UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017305
Receipt number R000019807
Scientific Title Lacrimal Stability Evaluation (Three-Dimensional Image Analysis of Anterior Segment) with Rebamipide Ophthalmic Solution
Date of disclosure of the study information 2015/05/01
Last modified on 2017/10/29 11:03:23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Lacrimal Stability Evaluation (Three-Dimensional Image Analysis of Anterior Segment) with Rebamipide Ophthalmic Solution

Acronym

Lacrimal Stability Evaluation with Rebamipide Ophthalmic Solution

Scientific Title

Lacrimal Stability Evaluation (Three-Dimensional Image Analysis of Anterior Segment) with Rebamipide Ophthalmic Solution

Scientific Title:Acronym

Lacrimal Stability Evaluation with Rebamipide Ophthalmic Solution

Region

Japan


Condition

Condition

Dry eye

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Evaluation of influence on tear stability after rebamipide instillation in the Dry Eye patients using AS-OCT

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Phase IV


Assessment

Primary outcomes

To evaluate tear stability treated with rebamipide ophthalmic solution

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Rebamipide ophthalmic solution
4 times / day, 4weeks

Interventions/Control_2

Control saline eyedrops
4 times / day, 4 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients who be classified the definition and diagnosis of Dry Eye 2006 and 20 years old or older
2) Patients who be obtained informed consent

Key exclusion criteria

1) Epiphora with suspicion (caused by Allergic conjumctivitis)
2) Meibomian grand dysfunction
3) Atresia puncti lacrimalis (e.g., punctal plug, surgical punctal occlusion)
4) Complication with the upheaval of the keratoconjunctive (e.g., conjunctivochalasis, pterygium)
5) Anatomical and functionl palpebral abnormality (e.g., lid closure imperfection)
6) Instillation of the glaucoma therapeutic drug
7) Patients who cannot be obtained informed consent

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Atsushi Shiraishi

Organization

Ehime University

Division name

Ophthalmology

Zip code


Address

Shizukawa, Toon, Ehime, Japan

TEL

089-960-5361

Email

shiraia@m.ehime-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Atsushi Shiraishi

Organization

Ehime University

Division name

Ophthalmology

Zip code


Address

Shitsukawa, Toon, Ehime

TEL

089-960-5361

Homepage URL


Email

shiraia@m.ehime-u.ac.jp


Sponsor or person

Institute

Department of Ophthalmology, Ehime University

Institute

Department

Personal name



Funding Source

Organization

Otsuka Pharmaceutical Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 05 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2015 Year 04 Month 01 Day

Date of IRB


Anticipated trial start date

2015 Year 05 Month 01 Day

Last follow-up date

2017 Year 10 Month 31 Day

Date of closure to data entry

2017 Year 10 Month 31 Day

Date trial data considered complete

2017 Year 10 Month 31 Day

Date analysis concluded

2017 Year 12 Month 31 Day


Other

Other related information



Management information

Registered date

2015 Year 04 Month 28 Day

Last modified on

2017 Year 10 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019807


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name